Intuitive Surgical (NASDAQ:ISRG) EVP Mark Brosius Sells 28 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Mark Brosius sold 28 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $360.21, for a total transaction of $10,085.88. Following the completion of the sale, the executive vice president directly owned 1,322 shares in the company, valued at $476,197.62. This trade represents a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Brosius also recently made the following trade(s):

• On Monday, July 27th, Mark Brosius sold 28 shares of Intuitive Surgical stock. The stock was sold at an average price of $344.00, for a total transaction of $9,632.00.
• On Friday, June 12th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The shares were sold at an average price of $414.13, for a total transaction of $10,353.25.
• On Wednesday, June 10th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The shares were sold at an average price of $424.14, for a total value of $9,755.22.
• On Monday, June 8th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The stock was sold at an average price of $420.12, for a total value of $9,662.76.
• On Friday, May 22nd, Mark Brosius sold 18 shares of Intuitive Surgical stock. The stock was sold at an average price of $439.80, for a total value of $7,916.40.
• On Wednesday, May 20th, Mark Brosius sold 18 shares of Intuitive Surgical stock. The stock was sold at an average price of $440.38, for a total value of $7,926.84.
• On Monday, May 18th, Mark Brosius sold 18 shares of Intuitive Surgical stock. The shares were sold at an average price of $422.47, for a total value of $7,604.46.

Intuitive Surgical Trading Down 2.4%

ISRG stock opened at $353.10 on Thursday. The business’s fifty day moving average price is $401.70 and its 200 day moving average price is $454.32. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88. The company has a market capitalization of $124.74 billion, a PE ratio of 40.45, a P/E/G ratio of 2.62 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.Intuitive Surgical’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period last year, the business posted $1.81 EPS. Research analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ISRG. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a report on Tuesday, May 19th. Mizuho set a $500.00 price target on shares of Intuitive Surgical and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Sanford C. Bernstein dropped their price target on shares of Intuitive Surgical from $750.00 to $685.00 and set an “outperform” rating for the company in a research note on Friday, July 17th. Evercore set a $430.00 price objective on Intuitive Surgical in a research report on Monday, July 6th. Finally, Piper Sandler set a $357.44 price objective on Intuitive Surgical in a research note on Monday. Twenty-one investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $517.21.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts remain broadly optimistic about Intuitive Surgical’s long-term prospects. Reports cite an average Wall Street price target of about $484 and one target of $685, implying significant upside from recent levels. The company’s installed da Vinci system base, recurring instrument and accessory revenue, and durable demand support the bullish view. Why Wall Street Thinks Intuitive Surgical Could Rise Intuitive Surgical Price Target
• Positive Sentiment: Management’s second-quarter commentary indicated durable platform demand and higher margin guidance, suggesting that procedure growth and profitability remain structurally attractive despite near-term volatility. ISRG Q2 Earnings Call Signals Durable Demand
• Positive Sentiment: A new awareness campaign with Deion “Coach Prime” Sanders could increase patient understanding of robotic-assisted surgery and support future procedure demand. Why Intuitive Surgical Shares Rose
• Neutral Sentiment: Intuitive Surgical overhauled its bylaws governing director nominations, shareholder proposals, and special meetings. The changes may improve governance clarity but also alter shareholder participation rights; analysts view the revisions alongside the stock’s weakness as part of a potential undervaluation case. Intuitive Surgical Undervaluation and Bylaw Changes
• Neutral Sentiment: Executive vice president Mark Brosius reported two small stock sales under a pre-arranged Rule 10b5-1 plan. Because the transactions represented roughly 2% of his holdings, they are unlikely to materially change the investment case. SEC Insider Trading Filing
• Negative Sentiment: The post-earnings selloff reflects investor caution despite quarterly results that exceeded expectations. Management warned of softer U.S. procedure growth and deferred care, raising concerns about near-term utilization and valuation. Intuitive Surgical Post-Earnings Selloff ISRG Q2 Earnings Call Signals

Hedge Funds Weigh In On Intuitive Surgical

Several hedge funds have recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth about $2,856,987,000. J. Stern & Co. LLP raised its stake in shares of Intuitive Surgical by 18,504.6% during the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock worth $1,204,788,000 after purchasing an additional 2,115,814 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Intuitive Surgical by 1,043.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock worth $760,124,000 after buying an additional 1,224,734 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Intuitive Surgical by 95.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after purchasing an additional 1,027,475 shares during the period. Finally, Polen Capital Management LLC purchased a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $477,225,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.